Navigation Links
Study Published in Journal of Vascular Surgery Confirms Superiority of Artegraft BCA to Cuffed ePTFE for Hemodialysis Access
Date:7/20/2011

NORTH BRUNSWICK, N.J., July 20, 2011 /PRNewswire/ -- Artegraft, Inc. announces that a three-year prospective, randomized clinical study published in the June 2011 issue of the Journal of Vascular Surgery confirms the superiority of Artegraft® Bovine Carotid Artery vascular grafts (BCA) to cuffed ePTFE grafts. Conducted at Massachusetts General Hospital, the study concluded that the BCA graft had significantly higher primary and assisted patency rates than the ePTFE graft, making Artegraft an excellent option for patients on hemodialysis who are not eligible for native arteriovenous fistulas.

The study results concluded that the Overall Primary Patency Rate at one year was 60 percent for Artegraft and 10 percent for ePTFE. For Assisted Primary Patency Rate at one year, Artegraft was 60 percent and ePTFE was 20 percent, according to the study results. After two years, the Assisted Primary Rate was 40 percent for Artegraft and 14 percent for ePTFE. Study results also concluded that there were less thrombosis and fewer interventions with the Artegraft BCA, as well as no pseudoaneurysms.

"The study validates the results that leading surgeons who have used Artegraft have experienced for 40 years," said Richard A. Gibson, President and Chief Executive Officer, Artegraft. "Our BCA grafts have been successfully used in thousands of patients. Its success is due to many factors, including the superior placement characteristics of Artegraft and that it is naturally accepted by the body."

A natural collagen vascular graft, Artegraft is processed to enhance long-term patency and
provide a tightly woven, cross-linked conduit that is flexible and compliant. It is especially ideal to utilize in patients with failed or immature native fistula; interposition in a fistula with a ruptured aneurysm; groin access; low protein conditions in which seroma formation may occur; and patients with hypotension. Patients suffering from an infected ePTFE graft or recurrent clotting with a synthetic graft or fistula are candidates for Artegraft, as well.

About Artegraft

Incorporated in 1993, Artegraft Inc. offers surgeons a biological alternative to synthetic grafts.  Artegraft's natural collagen matrix has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Artegraft was the first vascular graft approved by the FDA in 1970 and has been in continuous clinical use for over 35 years. 

For more information, visit www.artegraft.com


'/>"/>
SOURCE Artegraft, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting
2. Upsher-Smith Laboratories Begins Phase III Study of Intranasal Midazolam for Rescue Treatment of Seizure Clusters in Epilepsy Patients
3. Bayer Study Reveals Gaps in Perception of Veterinary Care Between Vets and Pet Owners
4. Study Confirms that OrbusNeichs Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
5. Metamark Genetics Announces Cancer Cell Study Highlighting Discovery of Key Molecules that Drive Progression of Malignant Melanoma in Humans
6. Exenatide tQT Study Showed No Prolongation of QT Interval
7. PicoCal Inc. Announces Completion of NSF Funded Research With a Number of New Products, Patents, Publications of Innovative Devices for Topographical Imaging, Thermomechanical Analysis, the Study of Local Mechanical Properties and High Throughput Ap
8. Edward Breast Imaging Expert Lauds Swedish Mammography Study
9. Council on Competitiveness Showcases Power of High Performance Computing in Case Study with GNS Healthcare
10. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
11. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)...  Recently Zymo Research announced an exclusive license ... Horvath,s Clock. Based on this technology, Zymo Research ... academic and biopharma scientific researchers to determine the ... sperm. The service quantifies changes in ... chronological age following drug treatments and identifies disease ...
(Date:12/5/2016)... , Dec. 5, 2016  BD (Becton, Dickinson and ... medical technology company, will demonstrate an enhanced technology platform ... technologies, including the company,s leading Pyxis™ and Alaris™ systems, ... (ASHP) 2016 Midyear Meeting being held in ... While national data show that approximately 68 percent ...
(Date:12/5/2016)... 5, 2016 Research and Markets has announced ... Test Market Size, Share, Development, Growth and Demand Forecast to 2022" ... ... female fertility and pregnancy rapid test market is expected to grow ... and pregnancy rapid test market is witnessing high growth, due to ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
(Date:12/5/2016)... ... December 05, 2016 , ... T.E.N., ... that nominations will be accepted from December 5, 2016 through March 3, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a ... design firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, ... exclusive licensing agreement three years ago to design and develop the kathy ireland® ...
(Date:12/5/2016)... York, NY (PRWEB) , ... December 05, 2016 ... ... companies to use a patent-pending blend of L-Citrulline and glutathione to enhance production ... Blend, a combination that studies have shown to produce NO twice as effectively ...
(Date:12/5/2016)... Nashville, Tennessee (PRWEB) , ... ... ... leader in strategic interoperability, today announced that the company will provide alerting ... platform. CIHIE has been recently awarded $1.7 million in federal funds as ...
Breaking Medicine News(10 mins):